UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
LIQUIDIA TECHNOLOGIES, INC., Petitioner
v.
UNITED THERAPEUTICS CORPORATION, Patent Owner
IPR2020-00770 U.S. Patent No. 9,604,901

PETITIONER'S UPDATED EXHIBIT LIST



Exhibit No.	Description of Document
1001	U.S. Patent No. 9,604,901 to Batra, et al. (the "'901 patent")
1002	Declaration of Jeffrey D. Winkler, Ph.D. ("Winkler Decl.")
1003	Curriculum Vitae of Dr. Jeffrey D. Winkler
1004	U.S. Patent No. 8,497,393 to Batra, et al. (the "'393 patent")
1005	SteadyMed Ltd. v. United Therapeutics Corp., IPR2016-00006, Paper 82 (PTAB March 31, 2017) ("IPR2016-00006")
1006	Prosecution History of the '901 patent
1007	U.S. Patent No. 6,765,117 to Moriarty, et al. (the "'117 patent")
1008	PCT Application No. WO 2005/007081 ("Phares")
1009	Moriarty, R.M., et al., "The Intramolecular Asymmetric Pauson- Khand Cyclization as a Novel and General Stereoselective Route to Benzindene Prostacyclins: Synthesis of UT-15 (Treprostinil)," J. Org. Chem. Vol. 69, No. 6, 1890-1902 (2004) ("Moriarty")
1010	Wiberg, K., Laboratory Technique in Organic Chemistry (1960), p.112 ("Wiberg")
1011	Schoffstall, A.M. et al., Microscale and Miniscale Organic Chemistry Laboratory Experiments, 2d ed. (2004) pp. 200-202 ("Schoffstall")
1012	Certified English translation of Japanese Patent App. No. 56- 122328A to Kawakami, et al. ("Kawakami")
1013	Ege, S., Organic Chemistry Second Edition, Ch. 14 Carboxylic Acids and Their Derivates I. Nucleophilic Substitution Reactions at the Carbonyl Group (1989) pp. 543-547 ("Ege")
1014	U.S. Patent No. 4,306,075 to Aristoff (the "'075 patent")
1015	Declaration of Sylvia Hall-Ellis, Ph.D.
1016	Prosecution History of the '393 patent



Exhibit No.	Description of Document
1017	Reply Declaration of Jeffrey D. Winkler, Ph.D.
1018	Deposition transcript of Rodolfo Pinal, dated February 10, 2021
1019	Gao, K., "Synthesis of A-Galceramides, (-)-Treprostinil, and Design and Synthesis of Anti-Viral Agents," Thesis submitted as partial fulfillment of the requirements for the degree of Doctor Of Philosophy in Chemistry in the Graduate College of the University of Illinois at Chicago, 2006
1020	Parks, B.W., et al., "Convenient Synthesis of 6,6-Bicyclic Malonamides: A New Class of Conformationally Preorganized Ligands for f-Block Ion Binding," J. Org. Chem., 71:9622-27 (2006)
1021	Hanessian, S., et al., "Structure-Based Organic Synthesis of a Tricyclic <i>N</i> -Malayamycin Analogue," J. Org. Chem., 71:9807-17 (2006)
1022	Frost, J.M., et al., "Synthesis and Structure – Activity Relationships of 3,8-Diazabicyclo[4.2.0]octane Ligands, Potent Nicotinic Acetylcholine Receptor Agonists," J. Med. Chem., 49:7843-53 (2006)
1023	Regan, J., et al., "Quinol-4-ones as Steroid A-Ring Mimetics in Nonsteroidal Dissociated Glucocorticoid Agonists," J. Med. Chem., 49:7887-96 (2006)
1024	Paulekuhn, G.S., et al., "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database," J. Med. Chem., 50:6665-72 (2007)
1025	Mak, K.K.W., et al., "Mannich Reactions in Room Temperature Ionic Liquids (RTILs): An Advanced Undergraduate Project of Green Chemistry and Structural Elucidation," J. Chem. Ed., 83(6):943-46 (2006)



Exhibit No.	Description of Document
1026	Supplemental Materials to Mak, K.K.W., et al., "Mannich Reactions in Room Temperature Ionic Liquids (RTILs): An Advanced Undergraduate Project of Green Chemistry and Structural Elucidation," J. Chem. Ed., 83(6):943-46 (2006)
1027	Baar, M.R., et al., "Enantiomeric Resolution of (±)-Mandelic Acid by (1 <i>R</i> ,2 <i>S</i> )-(–)-Ephedrine," J. Chem. Ed., 82(7):1040-42 (2005)
1028	Supplemental Materials for Baar, M.R., et al., "Enantiomeric Resolution of (±)-Mandelic Acid by (1 <i>R</i> ,2 <i>S</i> )-(–)-Ephedrine," J. Chem. Ed., 82(7):1040-42 (2005)
1029	Brigandi, L.M., et al., "Synthesis and Analysis of Copper Hydroxy Double Salts," J. Chem. Educ., 82(11):1662 (2005)
1030	Supplemental Material for Online Publication for Brigandi, L.M., et al., "Synthesis and Analysis of Copper Hydroxy Double Salts," J. Chem. Educ., 82(11):1662 (2005)
1031	Hamilton, "Experiment #5: Resolution of ( <i>R</i> , <i>S</i> )-1-Phenylethylamine via Diastereoisomer formation with ( <i>2R</i> ),( <i>3R</i> )-Tartaric Acid," Laboratory Manual for Chemistry 202, Organic Chemistry Laboratory I at Mount Holyoke College (2006)
1032	Yadav, J.S., et al., "A concise and stereoselective synthesis of both enantiomers of altholactone and isoaltholactone," Tetrahedron Letters, 44:5831-33 (2003)
1033	Takadoi, M., et al., "Synthetic studies of himbacine, a potent antagonist of the muscarinic M <sub>2</sub> subtype receptor 1. Stereoselective total synthesis and antagonistic activity of enantiomeric pairs of himbacine and (2'S,6'R)-diepihimbacine, 4-epihimbacine, and novel himbacine congeners," Tetrahedron 58 (2002) 9903–23
1034	Berge, S.M., et al., "Pharmaceutical Salts," J. Pharm. Scis., 66(1):1-19 (1977)



Exhibit No.	Description of Document
1035	Excerpts from Loewenthal, H.J.E., et al., A Guide for the Perplexed Organic Experimentalist, Chapter 4: Running Small-scale Reactions in the Research Laboratory, pp. 87-119, 2d ed. (1990)
1036	Heidelberger, M., An Advanced Laboratory Manual of Organize Chemistry (1928)
1037	Product Information for Remodulin (2006) ("Remodulin Label")
1038	Excerpt from Hawley's Condensed Chemical Dictionary, 15th ed. (2007)
1039	Refiled Declaration of Jeffrey D. Winkler, Ph.D. (Ex. 1002)
1040	Signature page to Ex. 1018 Deposition transcript of Rodolfo Pinal, dated February 10, 2021
1041	Declaration of Deepa Kannappan in Support of Motion for <i>Pro Hac Vice</i> Admission
1042	Biography of Deepa Kannappan
1043	Highlighted Patent Owner's Response to Petition
1044	Highlighted Declaration of Rodolfo Pinal, Ph.D. (Ex. 2002)
1045	Highlighted Declaration of Rodolfo Pinal, Ph.D. Supporting United Therapeutic Corporation's Patent Owner Response (Ex. 2025)
1046	Highlighted Patent Owner's Sur-Reply
1047	Japanese Patent App. No. 56-122328A to Kawakami, et al. (Japanese), previously submitted as Ex. 1006 in <i>Steadymed Ltd. v. United Therapeutics Corp.</i> , IPR2016-00006
1048	Certified English translation of Japanese Patent App. No. 56-122328A to Kawakami, et al., previously submitted as Ex. 1007 in <i>Steadymed Ltd.</i> v. <i>United Therapeutics Corp.</i> , IPR2016-00006



# DOCKET A L A R M

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

